Astellas Sues U.S.-Based Hospira For Infringing Adenocard Patent
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma filed a suit against Hospira alleging the U.S. firm infringed on a patent for Adenocard (adenosine) for diagnosing heart blockage.